Status: Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Participants needed: 665
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Updated: Jun 2, 2026Locations: 17
Eligibility criteria
Histologically documented locally advanced and unresectable or metastatic NSCLC,... [+4]
Malignancy within the last 2 years as specified in the protocol [+1]